FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC - OncLive

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC  OncLive

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - nejm.org

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  nejm.org

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - Cancer Network

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  Cancer Network

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC - AJMC.com Managed M...

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC  AJMC.com Managed Markets Network

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC - OncLive

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC  OncLive

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy i...

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement  Frontiers

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer - PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer  PMLiVE

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC - www.oncnursingnews.com/

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC  www.oncnursingnews.com/

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangeme...

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review  ASCO Journals

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial - Medpage Today

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial  Medpage Today

Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC - BioSpace

Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC  BioSpace

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in ...

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib  Wiley Online Library

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil...

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD  OncLive

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management - OncLive

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management  OncLive

State of the Science Summit - Lung Cancer: Chaired by Noman Ashraf, MD - OncLive

State of the Science Summit - Lung Cancer: Chaired by Noman Ashraf, MD  OncLive

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer - OncLive

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer  OncLive

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer - PMLiVE

Roche’s ALK inhibitor Alecensa granted EC approval to treat early-stage lung cancer  PMLiVE

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for peo...

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for people with ALK-positive early-stage lung cancer  Canada NewsWire

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-...

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer  GlobeNewswire

Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke - AHA Journals

Inhibition of Anaplastic Lymphoma Kinase Protects From Ischemic Stroke  AHA Journals

A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis re...

A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib  Wiley Online Library

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature.com

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - nejm.org

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  nejm.org

In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer - Medpage Today

In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer  Medpage Today

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK -Positive Non–Small-Cell Lung Cancer...

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK -Positive Non–Small-Cell Lung Cancer: AF-001JP  ASCO Journals

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using phys...

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib  Frontiers

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature.com

Mutations in the anaplastic lymphoma kinase (ALK) kinase domain. - ResearchGate

Mutations in the anaplastic lymphoma kinase (ALK) kinase domain.  ResearchGate

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision...

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision Oncology  Nature.com

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Global Alectinib Market Expected to Surge at 7.5% CAGR from 2022 to 2030 As Revealed In New Repor...

Global Alectinib Market Expected to Surge at 7.5% CAGR from 2022 to 2030 As Revealed In New Report  WhaTech

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC - Targeted Oncology

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC  Targeted Oncology

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiothe...

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib  Frontiers

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 - Nature.com

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1  Nature.com

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC - PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC  PMLiVE

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination ...

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors  Nature.com

Choosing Between ALK Inhibitors in the Treatment of NSCLC - OncLive

Choosing Between ALK Inhibitors in the Treatment of NSCLC  OncLive

FDA clears Roche’s Alecensa for adjuvant use in NSCLC - pharmaphorum

FDA clears Roche’s Alecensa for adjuvant use in NSCLC  pharmaphorum

Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023 - AJMC.com Managed Markets Network

Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023  AJMC.com Managed Markets Network

Alectinib Market: Report Trends and Future Forecast Until (2024-2034) - IndiaPolitics.com

Alectinib Market: Report Trends and Future Forecast Until (2024-2034)  IndiaPolitics.com

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy - Targeted Oncology

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy  Targeted Oncology

Genentech oncology treatment granted first-of-a-kind approval - European Pharmaceutical Review

Genentech oncology treatment granted first-of-a-kind approval  European Pharmaceutical Review

Roche Korea’s ALK-positive lung cancer drug gets expanded indication - KBR

Roche Korea’s ALK-positive lung cancer drug gets expanded indication  KBR

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo...

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo  Nature.com

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometr...

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging  Nature.com

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - Oncology News Central

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC  Oncology News Central

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

Swiss giant Roche given green light for lung cancer drug in Canada - SWI swissinfo.ch in English

Swiss giant Roche given green light for lung cancer drug in Canada  SWI swissinfo.ch in English

Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive ana...

Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive anaplastic large cell lymphoma: A single institutional experience  Wiley Online Library

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive n...

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report  Wiley Online Library

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lun...

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer  ASCO Daily News

Alectinib surpasses crizotinib for untreated ALK -positive NSCLC - The Lancet

Alectinib surpasses crizotinib for untreated ALK -positive NSCLC  The Lancet

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive n...

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report  Wiley Online Library

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the r...

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance  The Lancet

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib i...

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK -positive NSCLC  Nature.com

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large...

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma  Wiley Online Library

Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Trou...

Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities  ASCO Daily News

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to a...

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases  Frontiers

Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully trea...

Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully treated by alectinib  Wiley Online Library

Defining the best-in-class in NSCLC - Nature.com

Defining the best-in-class in NSCLC  Nature.com

Roche's Alecensa Lowers Recurrence in Adjuvant NSCLC, But Experts Await Overall Survival Data - P...

Roche's Alecensa Lowers Recurrence in Adjuvant NSCLC, But Experts Await Overall Survival Data  Precision Medicine Online

J-ALEX: alectinib versus crizotinib in ALK -positive lung cancer - The Lancet

J-ALEX: alectinib versus crizotinib in ALK -positive lung cancer  The Lancet

Roche Claims ‘Unprecedented’ Phase III NSCLC Victory for Oral ALK Inhibitor Alecensa - BioSpace

Roche Claims ‘Unprecedented’ Phase III NSCLC Victory for Oral ALK Inhibitor Alecensa  BioSpace

ALK‐Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib - Wiley Online Library

ALK‐Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib  Wiley Online Library

Potential combined drug therapy for lung cancer - EurekAlert

Potential combined drug therapy for lung cancer  EurekAlert

Levy Discusses Treatment Options for ALK-Rearranged NSCLC - Targeted Oncology

Levy Discusses Treatment Options for ALK-Rearranged NSCLC  Targeted Oncology

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC - Nature.com

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC  Nature.com

Food-Drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in...

Food-Drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in JNCCN  PR Newswire

Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC) - Clini...

Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)  Clinical Trials Arena

Dr Husain on Developments in ALK+ NSCLC - OncLive

Dr Husain on Developments in ALK+ NSCLC  OncLive

Alecensa (alectinib) Cancer Medication - Cancer Health Treatment News

Alecensa (alectinib) Cancer Medication  Cancer Health Treatment News

Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhi...

Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis  Wiley Online Library

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer -...

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer  FiercePharma

Rapid Readouts: Final Analysis of KEYNOTE-189 - OncLive

Rapid Readouts: Final Analysis of KEYNOTE-189  OncLive

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer - Targeted Oncology

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer  Targeted Oncology

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC - OncLive

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC  OncLive

Dr Danish on the Use of Novel Radiotherapy Approaches in Cancer Care - OncLive

Dr Danish on the Use of Novel Radiotherapy Approaches in Cancer Care  OncLive

Dr. Shaw Discusses Lorlatinib in Lung Cancer - OncLive

Dr. Shaw Discusses Lorlatinib in Lung Cancer  OncLive

Potential combined drug therapy for lung cancer - Asia Research News

Potential combined drug therapy for lung cancer  Asia Research News

Treating Progressive NSCLC: What to Do When Your Treatment Stops Working - Healthline

Treating Progressive NSCLC: What to Do When Your Treatment Stops Working  Healthline

Levy Compares Trials of ALK-Targeted Therapy for Patients With Metastatic NSCLC - Targeted Oncology

Levy Compares Trials of ALK-Targeted Therapy for Patients With Metastatic NSCLC  Targeted Oncology

'Transformative' lung cancer treatment adds years to patients' lives - Milwaukee Journal Sentinel

'Transformative' lung cancer treatment adds years to patients' lives  Milwaukee Journal Sentinel

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy - ...

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy  The Lancet

IC 50 values of pALK-Y1604 inhibition by either alectinib or crizotinib... - ResearchGate

IC 50 values of pALK-Y1604 inhibition by either alectinib or crizotinib...  ResearchGate

ALECENSA (alectinib) for Metastatic Non-small Cell Lung Cancer - Cancer Therapy Advisor

ALECENSA (alectinib) for Metastatic Non-small Cell Lung Cancer  Cancer Therapy Advisor

Figure 3. Progression-free survival by IRC Shown is the Kaplan-Meier... - ResearchGate

Figure 3. Progression-free survival by IRC Shown is the Kaplan-Meier...  ResearchGate

Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancer - Medpage Today

Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancer  Medpage Today

Dr. Paik Discusses Advances in Squamous Cell Lung Cancer - OncLive

Dr. Paik Discusses Advances in Squamous Cell Lung Cancer  OncLive

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumo...

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas  Nature.com

Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug - HealthDay

Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug  HealthDay

ESMO: Roche's Alecensa staves off lung cancer recurrence en route to postsurgery expansion - Fier...

ESMO: Roche's Alecensa staves off lung cancer recurrence en route to postsurgery expansion  FiercePharma